Total compensation · 2025
$32.5M
$32,530,984 as reported in AbbVie Inc.'s proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
| Year |
|---|
| Salary |
|---|
| Bonus |
|---|
| Stock awards |
|---|
| Option awards |
|---|
| Incentive plan |
|---|
| Other |
|---|
| Total |
|---|
| Filing |
|---|
| 2025 | $1.7M | $0 | $13.3M | $3.2M | $5.2M | $9.2M | $32.5M | SEC |
| 2024 | $1.6M | $0 | $7.9M | $1.9M | $4.6M | $2.5M | $18.5M | SEC |
| 2023 | $1.4M | $0 | $5.4M | $1.4M | $3M | $3.2M | $14.4M | SEC |
| 2022 | $1.3M | $0 | $4.7M | $1.1M | $2.5M | $159K | $9.8M | SEC |
| 2021 | $1.1M | $0 | $4.3M | $1.1M | $2.6M | $61.4K | $11.7M | SEC |
| 2020 | $1.1M | $0 | $5.4M | $1.3M | $2.1M | $49.4K | $13.5M | SEC |
| 2019 | $1.3M | $0 | $3.2M | $808.6K | $2.4M | $245.5K | $9.5M | SEC |
| 2018 | $553.7K | $0 | $724K | $173.7K | $950K | $717.5K | $3.1M | SEC |
| 2017 | $1M | $0 | $3.7M | $981K | $2M | $772.9K | $8.4M | SEC |
| 2016 | $961K | $0 | $3.4M | $850.9K | $1.6M | $476.6K | $7.2M | SEC |
| 2015 | $918.1K | $0 | $3.1M | $1M | $1.2M | $294.8K | $6.6M | SEC |
| 2014 | $503.8K | $1M | $7.7M | $734.9K | $1.2M | $394K | $11.5M | SEC |
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
Sep 10, 2026https://www.zacks.com/stock/news/2987952/abbvie-s-immunology-franchise-from-skyrizi-rinvoq-to-what-s-next?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2987952sentiment +0.90
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie
Sep 10, 2026https://seekingalpha.com/article/4945003-adarx-pharmaceuticals-seeks-ipo-on-strong-collaboration-deal-with-abbviesentiment +0.30
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
Sep 4, 2026https://www.zacks.com/stock/news/2985168/abbv-s-etentamig-meets-goals-in-phase-iii-multiple-myeloma-study?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2985168sentiment +0.80
5 Reasons To Buy Clinuvel Pharmaceuticals After Its Nasdaq Uplisting
Sep 2, 2026https://seekingalpha.com/article/4942443-5-reasons-to-buy-clinuvel-pharmaceuticals-after-its-nasdaq-uplistingsentiment -0.20
FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?
Aug 23, 2026https://www.fool.com/coverage/etfs/2026/08/23/fhlc-vs-pjp-which-healthcare-etf-is-the-better-buy-for-investors/sentiment +0.10
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
Aug 21, 2026https://www.prnewswire.com/news-releases/abbvie-to-present-new-data-at-wclc-2026-showcasing-innovation-across-lung-cancer-pipeline-302856994.htmlsentiment +0.60
